{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6846e583cca944a48e6715d3/69f9a3699d4faa15062010ec?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6846e583cca944a48e6715d3/1777967868035-49ee38d9-7aaf-4c63-b8a8-2cc96d7810c1.jpeg?height=200","description":"<p>95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.</p><p><br></p><p>How do leading CDMOs move beyond scale to become true strategic partners?</p><p><br></p><p>This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships. </p><p><br></p><p>In this episode, John Gagliardi covers:</p><p><br></p><p>- How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply.</p><p>- Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies.</p><p>- What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market.</p><p>- The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem.</p><p>- Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility.</p><p><br></p><p>If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time. </p><p><br></p><p>Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens.</p><p><br></p><p>Follow ARTO</p><p>LinkedIn: https://www.linkedin.com/company/artotalent</p><p>Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng</p><p>Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&amp;utm_source=qr</p><p>TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&amp;_r=1</p><p>Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575</p><p>Website: https://arto-talent.com/</p><p>Youtube: https://www.youtube.com/@artotalent</p><p><br></p><p>John Gagliardi</p><p>Sales Director at Samsung Biologics</p><p>LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/</p><p><br></p><p>Harry Sloan</p><p>CDMO BD Lead at ARTO</p><p>LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D</p><p><br></p><p>Timestamps:</p><p>00:00 Introduction from New York and conference spotlight</p><p>00:42 Samsung Biologics as a pure-play CDMO</p><p>02:10 Building strategic customer partnerships</p><p>03:45 Differentiation beyond standard CDMO models</p><p>05:01 Building credibility in ADC manufacturing</p><p>07:53 Technical collaboration and winning partnerships</p><p>09:07 Lilly Gateway Labs collaboration</p><p>11:40 Growth trajectory and future modalities</p><p>13:19 Scaling while maintaining quality</p><p>15:00 Patient impact and personal motivation</p><p>16:35 Closing remarks</p><p><br></p><p>#MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership</p>","author_name":"ARTO Talent"}